You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameTheophylline
Accession NumberDB00277  (APRD00082, DB09359)
TypeSmall Molecule
GroupsApproved
DescriptionA methylxanthine derivative from tea with diuretic, smooth muscle relaxant, bronchial dilation, cardiac and central nervous system stimulant activities. Mechanistically, theophylline acts as a phosphodiesterase inhibitor, adenosine receptor blocker, and histone deacetylase activator. Theophylline is marketed under several brand names such as Uniphyl and Theochron, and it is indicated mainly for asthma, bronchospasm, and COPD.
Structure
Thumb
Synonyms
1,3-dimethyl-7H-purine-2,6-dione
1,3-dimethylxanthine
Theophyllin
Theophylline anhydrous
Theophylline, anhydrous
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Elixir De TheophyllineElixir80 mgOralLaboratoire Atlas Inc1985-12-31Not applicableCanada
PMS-theophylline ElixirElixir80 mgOralPharmascience Inc1983-12-312016-10-28Canada
Pulmophylline ElxElixir80 mgOralLaboratoire Riva Inc1979-12-31Not applicableCanada
Quibron T SR Tab 300mgTablet, extended release300 mgOralBristol Labs Division Of Bristol Myers Squibb1982-12-312004-08-05Canada
Slo-bid 100Capsule, extended release100 mgOralAventis Pharma Inc1987-12-312003-07-22Canada
Slo-bid 200Capsule, extended release200 mgOralAventis Pharma Inc1987-12-312003-07-22Canada
Slo-bid 300Capsule, extended release300 mgOralAventis Pharma Inc1987-12-312002-07-29Canada
Slo-bid 50Capsule, extended release50 mgOralAventis Pharma Inc1988-12-312003-07-22Canada
Teva-theophylline SRTablet, extended release200 mgOralTeva Canada Limited1996-12-19Not applicableCanada
Teva-theophylline SRTablet, extended release300 mgOralTeva Canada Limited1998-04-16Not applicableCanada
Teva-theophylline SRTablet, extended release100 mgOralTeva Canada Limited1998-04-16Not applicableCanada
Theo ERTablet, extended release600 mgOralAa Pharma Inc2011-06-23Not applicableCanada
Theo ERTablet, extended release400 mgOralAa Pharma Inc2011-06-23Not applicableCanada
Theo-dur 100 mgTablet, extended release100 mgOralAstrazeneca Canada Inc1979-12-312001-11-21Canada
Theo-dur 200 mgTablet, extended release200 mgOralAstrazeneca Canada Inc1979-12-312003-04-29Canada
Theo-dur 300 mgTablet, extended release300 mgOralAstrazeneca Canada Inc1979-12-312003-04-29Canada
Theo-dur 450 mgTablet, extended release450 mgOralAstrazeneca Canada Inc1988-12-312001-07-30Canada
Theo-SR 300 Srt 300mgTablet, extended release300 mgOralRhone Poulenc Rorer Canada Inc.1987-12-311999-08-12Canada
TheolairLiquid80 mgOralValeant Canada Lp Valeant Canada S.E.C.1992-12-31Not applicableCanada
Theolair SR Tab 200mgTablet, extended release200 mgOral3 M Pharmaceuticals, A Division Of 3 M Canada Company1993-12-312002-07-09Canada
Theolair SR Tab 250mgTablet, extended release250 mgOral3 M Pharmaceuticals, A Division Of 3 M Canada Company1993-12-312002-07-09Canada
Theolair SR Tab 300mgTablet, extended release300 mgOral3 M Pharmaceuticals, A Division Of 3 M Canada Company1979-12-312002-07-09Canada
Theolair SR Tab 500mgTablet, extended release500 mgOral3 M Pharmaceuticals, A Division Of 3 M Canada Company1993-12-312002-07-09Canada
Theolair Tab 125mgTablet125 mgOral3 M Pharmaceuticals, A Division Of 3 M Canada Company1993-12-312002-07-09Canada
Theolair Tab 250mgTablet250 mgOral3 M Pharmaceuticals, A Division Of 3 M Canada Company1993-12-312002-07-09Canada
Theophylline 80mg/15mlLiquid80 mgOralDesbergers LtÉe, Division Of Technilab Inc.1969-12-311999-09-17Canada
Theophylline ElixirElixir80 mgOralTherapex Division De E Z Em Canada Inc1980-12-311997-04-04Canada
Theophylline ElixirElixir80 mgOralPro Doc Limitee1965-12-312003-07-31Canada
Theophylline ElxElixir80 mgOralTechnilab Pharma Inc.1981-12-312006-07-28Canada
Theophylline In DextroseInjection, solution400 mg/100mLIntravenousHospira, Inc.1984-01-02Not applicableUs
Theophylline In DextroseInjection, solution80 mg/100mLIntravenousBaxter Healthcare Corporation1982-07-26Not applicableUs
Theophylline In DextroseInjection, solution320 mg/100mLIntravenousHospira, Inc.1984-01-02Not applicableUs
Theophylline In DextroseInjection, solution160 mg/100mLIntravenousBaxter Healthcare Corporation1982-07-26Not applicableUs
Theophylline In DextroseInjection, solution160 mg/100mLIntravenousHospira, Inc.1984-01-02Not applicableUs
Theophylline In DextroseInjection, solution200 mg/100mLIntravenousHospira, Inc.1984-01-02Not applicableUs
Theophylline Srt 300mgTablet, extended release300 mgOralForest Labs Inc1985-12-311999-05-03Canada
Theophylline Sustained Release Tab 100mgTablet, extended release100 mgOralForest Labs Inc1985-12-311999-05-03Canada
Theophylline Sustained Release Tab 200mgTablet, extended release200 mgOralForest Labs Inc1985-12-311999-05-03Canada
UniphylTablet, extended release600 mgOralPurdue Pharma1987-12-31Not applicableCanada
UniphylTablet, extended release400 mgOralPurdue Pharma1987-12-31Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-theo ERTablet, extended release600 mgOralApotex IncNot applicableNot applicableCanada
Apo-theo ERTablet, extended release400 mgOralApotex IncNot applicableNot applicableCanada
Apo-theo-LA Srt 100mgTablet, extended release100 mgOralApotex Inc1993-12-31Not applicableCanada
Apo-theo-LA Srt 200mgTablet, extended release200 mgOralApotex Inc1993-12-31Not applicableCanada
Apo-theo-LA Srt 300mgTablet, extended release300 mgOralApotex Inc1993-12-31Not applicableCanada
ElixophyllinLiquid80 mg/15mLOralAtlantic Biologicals Corps2009-10-01Not applicableUs
ElixophyllinLiquid80 mg/15mLOralNostrum Laboratories, Inc.2009-10-01Not applicableUs
ElixophyllinLiquid80 mg/15mLOralCaraco Pharma, Inc.2009-10-01Not applicableUs
Theo-24Capsule, extended release300 mg/1OralUCB, Inc.1998-02-202016-01-07Us
Theo-24Capsule, extended release200 mg/1OralActient Pharmaceuticals, LLC2014-08-25Not applicableUs
Theo-24Capsule, extended release400 mg/1OralUCB, Inc.1998-01-092016-01-07Us
Theo-24Capsule, extended release300 mg/1OralActient Pharmaceuticals, LLC2014-08-25Not applicableUs
Theo-24Capsule, extended release300 mg/1OralCardinal Health1983-08-222016-10-13Us
Theo-24Capsule, extended release100 mg/1OralUCB, Inc.1998-04-212016-01-07Us
Theo-24Capsule, extended release400 mg/1OralActient Pharmaceuticals, LLC2014-08-25Not applicableUs
Theo-24Capsule, extended release100 mg/1OralActient Pharmaceuticals, LLC2014-08-25Not applicableUs
Theo-24Capsule, extended release200 mg/1OralUCB, Inc.1998-01-202016-01-07Us
TheophyllineTablet, extended release200 mg/1OralREMEDYREPACK INC.2011-04-272016-10-13Us
TheophyllineSolution80 mg/15mLOralMarlex Pharmaceuticals Inc2016-02-01Not applicableUs
TheophyllineTablet, extended release200 mg/1OralAv Kare, Inc.2014-12-15Not applicableUs
TheophyllineSolution80 mg/15mLOralPharmaceutical Associates, Inc.2008-11-03Not applicableUs
TheophyllineTablet, extended release200 mg/1OralCardinal Health2008-11-13Not applicableUs
TheophyllineSolution80 mg/15mLOralSilarx Pharmaceuticals, Inc2011-04-13Not applicableUs
TheophyllineTablet, extended release100 mg/1OralPliva Inc.1990-09-30Not applicableUs
TheophyllineTablet, extended release200 mg/1OralMajor Pharmaceuticals2008-11-13Not applicableUs
TheophyllineTablet, extended release200 mg/1Oralbryant ranch prepack2010-09-13Not applicableUs
TheophyllineTablet, extended release300 mg/1OralAlembic Pharmaceuticals Limited2010-11-01Not applicableUs
TheophyllineTablet, extended release300 mg/1OralHeritage Pharmaceuticals Inc.2010-11-01Not applicableUs
TheophyllineSolution80 mg/15mLOralTris Pharma Inc2012-08-02Not applicableUs
TheophyllineTablet, extended release300 mg/1OralAv Kare, Inc.2014-12-15Not applicableUs
TheophyllineTablet, extended release300 mg/1OralCardinal Health2008-11-13Not applicableUs
TheophyllineTablet, extended release200 mg/1OralLake Erie Medical DBA Quality Care Products LLC1990-09-30Not applicableUs
TheophyllineTablet, extended release600 mg/1OralGlenmark Pharmaceuticals Inc., Usa2010-07-13Not applicableUs
TheophyllineTablet, extended release200 mg/1OralPhysicians Total Care, Inc.1996-12-19Not applicableUs
TheophyllineTablet, extended release450 mg/1OralPliva Inc.1993-10-31Not applicableUs
TheophyllineTablet, extended release450 mg/1OralAlembic Pharmaceuticals Limited2010-11-01Not applicableUs
TheophyllineTablet, extended release300 mg/1OralMajor Pharmaceuticals2008-11-13Not applicableUs
TheophyllineTablet, extended release100 mg/1Oralbryant ranch prepack1990-09-30Not applicableUs
TheophyllineTablet, extended release300 mg/1OralAlembic Pharmaceuticals Inc.2016-01-29Not applicableUs
TheophyllineTablet, extended release300 mg/1OralState of Florida DOH Central Pharmacy2013-01-01Not applicableUs
TheophyllineTablet, extended release300 mg/1OralPliva Inc.1990-09-30Not applicableUs
TheophyllineTablet, extended release450 mg/1OralHeritage Pharmaceuticals Inc.2010-11-01Not applicableUs
TheophyllineTablet, extended release200 mg/1OralAmerican Health Packaging2015-03-31Not applicableUs
TheophyllineTablet, extended release300 mg/1OralClinical Solutions Wholesale1990-09-30Not applicableUs
TheophyllineSolution80 mg/15mLOralLiberta Pharma Inc2013-05-032016-10-13Us
TheophyllineTablet, extended release300 mg/1OralLake Erie Medical DBA Quality Care Products LLC1990-09-30Not applicableUs
TheophyllineTablet, extended release400 mg/1OralGlenmark Pharmaceuticals Inc., Usa2010-07-13Not applicableUs
TheophyllineTablet, extended release300 mg/1OralPhysicians Total Care, Inc.2007-09-17Not applicableUs
TheophyllineTablet, extended release300 mg/1Oralbryant ranch prepack1990-09-30Not applicableUs
TheophyllineTablet, extended release450 mg/1OralAlembic Pharmaceuticals Inc.2016-01-29Not applicableUs
TheophyllineTablet, extended release300 mg/1OralA S Medication Solutions Llc1990-09-30Not applicableUs
TheophyllineTablet, extended release200 mg/1OralPliva Inc.1990-09-30Not applicableUs
TheophyllineTablet, extended release200 mg/1OralPreferred Pharmaceuticals, Inc.2014-08-20Not applicableUs
TheophyllineTablet, extended release100 mg/1OralMajor Pharmaceuticals2008-11-13Not applicableUs
TheophyllineSolution80 mg/15mLOralCranbury Pharmaceuticals Inc2014-11-03Not applicableUs
TheophyllineTablet, extended release100 mg/1OralPhysicians Total Care, Inc.2007-07-04Not applicableUs
TheophyllineTablet, extended release100 mg/1OralAv Kare, Inc.2014-12-15Not applicableUs
TheophyllineTablet, extended release300 mg/1OralAmerican Health Packaging2015-03-312015-12-29Us
Theophylline (anhydrous)Tablet, extended release200 mg/1OralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Theophylline (anhydrous)Tablet, extended release600 mg/1OralCarilion Materials Management2007-06-01Not applicableUs
Theophylline (anhydrous)Tablet, extended release600 mg/1OralNostrum Laboratories, Inc.2007-06-01Not applicableUs
Theophylline (anhydrous)Tablet, extended release300 mg/1OralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Theophylline (anhydrous)Tablet, extended release400 mg/1OralNostrum Laboratories, Inc.2007-06-01Not applicableUs
Theophylline AnhydrousTablet, extended release400 mg/1OralRhodes Pharmaceuticals L.P.2012-02-02Not applicableUs
Theophylline AnhydrousTablet, extended release400 mg/1OralCarilion Materials Management2012-02-02Not applicableUs
Theophylline AnhydrousTablet, extended release600 mg/1OralRhodes Pharmaceuticals L.P.2012-02-02Not applicableUs
Theophylline Extended ReleaseTablet, extended release300 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs1990-04-30Not applicableUs
Theophylline Extended ReleaseTablet, extended release200 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs1990-04-30Not applicableUs
Theophylline Extended ReleaseTablet300 mg/1OralREMEDYREPACK INC.2011-07-07Not applicableUs
Theophylline(anhydrous)Tablet, extended release400 mg/1OralPACK Pharmaceuticals, LLC2010-09-15Not applicableUs
UniphylTablet400 mg/1OralPurdue Pharmaceutical Products LP1982-09-01Not applicableUs
UniphylTablet600 mg/1OralPurdue Pharmaceutical Products LP1996-06-07Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
Quibron-TNot Available
RespbidNot Available
Slo-BidNot Available
Theo 24Not Available
Theo-DurNot Available
Theodur GNot Available
Brand mixtures
NameLabellerIngredients
I D M Expectorant TabRougier Pharma Division Of Ratiopharm Inc
Idm TabRougier Pharma Division Of Ratiopharm Inc
Ratio-theo-broncRatiopharm Inc Division Of Teva Canada Limited
SenophyllinePhysician Therapeutics Llc
Tedral TabParke Davis Division, Warner Lambert Canada Inc.
Theophylline 0.8mg and 5% Dextrose InjBaxter Corporation
Theophylline 0.8mg/ml In 5% Dextrose InjHospira Healthcare Corporation
Theophylline 1.6mg and 5% Dextrose InjBaxter Corporation
Theophylline 4mg and 5% Dextrose InjBaxter Corporation
Theophylline In DextroseB. Braun Medical Inc.
Theophylline Rougier ElixirRougier Pharma Division Of Ratiopharm Inc
Salts
Name/CASStructureProperties
Theophylline sodium glycinate
8000-10-0
Thumb
  • InChI Key: AIJQWRAOMFRHTQ-UHFFFAOYSA-M
  • Monoisotopic Mass: 277.07869817
  • Average Mass: 277.216
DBSALT001603
Categories
UNII0I55128JYK
CAS number58-55-9
WeightAverage: 180.164
Monoisotopic: 180.06472552
Chemical FormulaC7H8N4O2
InChI KeyZFXYFBGIUFBOJW-UHFFFAOYSA-N
InChI
InChI=1S/C7H8N4O2/c1-10-5-4(8-3-9-5)6(12)11(2)7(10)13/h3H,1-2H3,(H,8,9)
IUPAC Name
1,3-dimethyl-2,3,6,7-tetrahydro-1H-purine-2,6-dione
SMILES
CN1C2=C(NC=N2)C(=O)N(C)C1=O
Pharmacology
IndicationFor the treatment of the symptoms and reversible airflow obstruction associated with chronic asthma and other chronic lung diseases, such as emphysema and chronic bronchitis.
Structured Indications
PharmacodynamicsTheophylline, an xanthine derivative chemically similar to caffeine and theobromine, is used to treat asthma and bronchospasm. Theophylline has two distinct actions in the airways of patients with reversible (asthmatic) obstruction; smooth muscle relaxation (i.e., bronchodilation) and suppression of the response of the airways to stimuli (i.e., non-bronchodilator prophylactic effects).
Mechanism of actionTheophylline relaxes the smooth muscle of the bronchial airways and pulmonary blood vessels and reduces airway responsiveness to histamine, methacholine, adenosine, and allergen. Theophylline competitively inhibits type III and type IV phosphodiesterase (PDE), the enzyme responsible for breaking down cyclic AMP in smooth muscle cells, possibly resulting in bronchodilation. Theophylline also binds to the adenosine A2B receptor and blocks adenosine mediated bronchoconstriction. In inflammatory states, theophylline activates histone deacetylase to prevent transcription of inflammatory genes that require the acetylation of histones for transcription to begin.
TargetKindPharmacological actionActionsOrganismUniProt ID
Adenosine receptor A1Proteinyes
antagonist
HumanP30542 details
Adenosine receptor A2aProteinyes
antagonist
HumanP29274 details
Adenosine receptor A2bProteinyes
antagonist
HumanP29275 details
cAMP-specific 3',5'-cyclic phosphodiesterase 4BProteinyes
inhibitor
HumanQ07343 details
cGMP-specific 3',5'-cyclic phosphodiesteraseProteinyes
inhibitor
HumanO76074 details
cAMP-specific 3',5'-cyclic phosphodiesterase 4AProteinyes
inhibitor
HumanP27815 details
cGMP-inhibited 3',5'-cyclic phosphodiesterase AProteinyes
inhibitor
HumanQ14432 details
Histone deacetylase 2Proteinyes
activator
HumanQ92769 details
Related Articles
AbsorptionTheophylline is rapidly and completely absorbed after oral administration in solution or immediate-release solid oral dosage form.
Volume of distribution
  • 0.3 to 0.7 L/kg
Protein binding40%, primarily to albumin.
Metabolism

Hepatic. Biotransformation takes place through demethylation to 1-methylxanthine and 3-methylxanthine and hydroxylation to 1,3-dimethyluric acid. 1-methylxanthine is further hydroxylated, by xanthine oxidase, to 1-methyluric acid. About 6% of a theophylline dose is N-methylated to caffeine. Caffeine and 3-methylxanthine are the only theophylline metabolites with pharmacologic activity.

SubstrateEnzymesProduct
Theophylline
1-MethylxanthineDetails
Theophylline
3-methylxanthineDetails
Theophylline
1,3-dimethyluric acidDetails
Theophylline
Not Available
CaffeineDetails
Route of eliminationTheophylline does not undergo any appreciable pre-systemic elimination, distributes freely into fat-free tissues and is extensively metabolized in the liver. Renal excretion of unchanged theophylline in neonates amounts to about 50% of the dose, compared to about 10% in children older than three months and in adults.
Half life8 hours
Clearance
  • 0.29 mL/kg/min [Premature neonates, postnatal age 3-15 days]
  • 0.64 mL/kg/min [Premature neonates, postnatal age 25-57 days]
  • 1.7 mL/kg/min [Children 1-4 years]
  • 1.6 mL/kg/min [Children 4-12 years]
  • 0.9 mL/kg/min [Children 13-15 years]
  • 1.4 mL/kg/min [Children 16-17 years]
  • 0.65 mL/kg/min [Adults (16-60 years), otherwise healthy non-smoking asthmatics]
  • 0.41 mL/kg/min [Elderly (>60 years), non-smokers with normal cardiac, liver, and renal function]
  • 0.33 mL/kg/min [Acute pulmonary edema]
  • 0.54 mL/kg/min [COPD >60 years, stable, non-smoker >1 year]
  • 0.48 mL/kg/min [COPD with cor pulmonale]
  • 1.25 mL/kg/min [Cystic fibrosis (14-28 years)]
  • 0.31 mL/kg/min [Liver disease cirrhosis]
  • 0.35 mL/kg/min [acute hepatitis]
  • 0.65 mL/kg/min [cholestasis]
  • 0.47 mL/kg/min [Sepsis with multi-organ failure]
  • 0.38 mL/kg/min [hypothyroid]
  • 0.8 mL/kg/min [hyperthyroid]
ToxicitySymptoms of overdose include seizures, arrhythmias, and GI effects.
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Caffeine MetabolismMetabolicSMP00028
SNP Mediated Effects
Interacting Gene/EnzymeSNP RS IDAllele nameDefining changeEffectReference(s)
Cytochrome P450 1A2
Gene symbol: CYP1A2
UniProt: P05177
Not Available-2964(G/A)A AllelePoor metabolizer, lower dose requirement12732846
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,10-PhenanthrolineThe serum concentration of Theophylline can be decreased when it is combined with 1,10-Phenanthroline.Experimental
3,4-DichloroisocoumarinThe serum concentration of Theophylline can be decreased when it is combined with 3,4-Dichloroisocoumarin.Experimental
4-(2-AMINOETHYL)BENZENESULFONYL FLUORIDEThe serum concentration of Theophylline can be decreased when it is combined with 4-(2-AMINOETHYL)BENZENESULFONYL FLUORIDE.Experimental
AbirateroneThe serum concentration of Theophylline can be increased when it is combined with Abiraterone.Approved
AcebutololAcebutolol may decrease the bronchodilatory activities of Theophylline.Approved
AcenocoumarolThe metabolism of Acenocoumarol can be decreased when combined with Theophylline.Approved
AcetaminophenThe metabolism of Acetaminophen can be decreased when combined with Theophylline.Approved
AdalimumabThe serum concentration of Theophylline can be decreased when it is combined with Adalimumab.Approved
AdenosineThe therapeutic efficacy of Adenosine can be decreased when used in combination with Theophylline.Approved, Investigational
AgomelatineThe serum concentration of Agomelatine can be increased when it is combined with Theophylline.Approved, Investigational
AlbendazoleThe metabolism of Albendazole can be decreased when combined with Theophylline.Approved, Vet Approved
Albumin-interferon alphaThe metabolism of Theophylline can be decreased when combined with Albumin-interferon alpha.Investigational
AllopurinolThe serum concentration of Theophylline can be increased when it is combined with Allopurinol.Approved
AlmotriptanThe metabolism of Almotriptan can be decreased when combined with Theophylline.Approved, Investigational
AlogliptinThe serum concentration of Theophylline can be decreased when it is combined with Alogliptin.Approved
AlosetronThe metabolism of Alosetron can be decreased when combined with Theophylline.Approved, Withdrawn
Alpha-1-proteinase inhibitorThe serum concentration of Theophylline can be decreased when it is combined with Alpha-1-proteinase inhibitor.Approved
AlprazolamThe therapeutic efficacy of Alprazolam can be decreased when used in combination with Theophylline.Approved, Illicit, Investigational
AlprenololAlprenolol may decrease the bronchodilatory activities of Theophylline.Approved, Withdrawn
AminophenazoneThe metabolism of Aminophenazone can be decreased when combined with Theophylline.Approved, Withdrawn
AminophyllineThe metabolism of Aminophylline can be decreased when combined with Theophylline.Approved
AmiodaroneThe metabolism of Theophylline can be decreased when combined with Amiodarone.Approved, Investigational
AmitriptylineThe metabolism of Amitriptyline can be decreased when combined with Theophylline.Approved
AmobarbitalThe serum concentration of Theophylline can be decreased when it is combined with Amobarbital.Approved, Illicit
AmprenavirThe serum concentration of Theophylline can be decreased when it is combined with Amprenavir.Approved
AnagrelideThe metabolism of Anagrelide can be decreased when combined with Theophylline.Approved
AntipyrineThe metabolism of Antipyrine can be decreased when combined with Theophylline.Approved
Antithrombin III humanThe serum concentration of Theophylline can be decreased when it is combined with Antithrombin III human.Approved
ApixabanThe metabolism of Apixaban can be decreased when combined with Theophylline.Approved
AprepitantThe serum concentration of Theophylline can be increased when it is combined with Aprepitant.Approved, Investigational
AprotininThe serum concentration of Theophylline can be decreased when it is combined with Aprotinin.Approved, Withdrawn
ArgatrobanThe serum concentration of Theophylline can be decreased when it is combined with Argatroban.Approved, Investigational
ArtemetherThe metabolism of Theophylline can be decreased when combined with Artemether.Approved
ASA404The metabolism of ASA404 can be decreased when combined with Theophylline.Investigational
AsenapineThe metabolism of Asenapine can be decreased when combined with Theophylline.Approved
AsunaprevirThe serum concentration of Theophylline can be decreased when it is combined with Asunaprevir.Approved, Investigational
AtazanavirThe metabolism of Theophylline can be decreased when combined with Atazanavir.Approved, Investigational
AtenololAtenolol may decrease the bronchodilatory activities of Theophylline.Approved
AtomoxetineThe metabolism of Theophylline can be decreased when combined with Atomoxetine.Approved
AV650The metabolism of AV650 can be decreased when combined with Theophylline.Approved, Investigational
AxitinibThe metabolism of Axitinib can be decreased when combined with Theophylline.Approved, Investigational
AzelastineThe metabolism of Azelastine can be decreased when combined with Theophylline.Approved
AzithromycinThe metabolism of Theophylline can be decreased when combined with Azithromycin.Approved
BarbexacloneThe serum concentration of Theophylline can be decreased when it is combined with Barbexaclone.Experimental
BarbitalThe serum concentration of Theophylline can be decreased when it is combined with Barbital.Illicit
BatimastatThe serum concentration of Theophylline can be decreased when it is combined with Batimastat.Experimental
BazedoxifeneThe serum concentration of Theophylline can be increased when it is combined with Bazedoxifene.Approved, Investigational
BenazeprilThe serum concentration of Theophylline can be decreased when it is combined with Benazepril.Approved, Investigational
BendamustineThe metabolism of Bendamustine can be decreased when combined with Theophylline.Approved, Investigational
BenzamidineThe serum concentration of Theophylline can be decreased when it is combined with Benzamidine.Experimental
Benzyl alcoholThe metabolism of Benzyl alcohol can be decreased when combined with Theophylline.Approved
BetaxololThe metabolism of Betaxolol can be decreased when combined with Theophylline.Approved
BexaroteneThe serum concentration of Theophylline can be decreased when it is combined with Bexarotene.Approved, Investigational
Bi201335The serum concentration of Theophylline can be decreased when it is combined with Bi201335.Investigational
BisoprololBisoprolol may decrease the bronchodilatory activities of Theophylline.Approved
BivalirudinThe serum concentration of Theophylline can be decreased when it is combined with Bivalirudin.Approved, Investigational
BoceprevirThe metabolism of Theophylline can be decreased when combined with Boceprevir.Approved
BopindololBopindolol may decrease the bronchodilatory activities of Theophylline.Approved
BortezomibThe metabolism of Theophylline can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Theophylline can be decreased when it is combined with Bosentan.Approved, Investigational
BromazepamThe therapeutic efficacy of Bromazepam can be decreased when used in combination with Theophylline.Approved, Illicit
BupivacaineThe metabolism of Bupivacaine can be decreased when combined with Theophylline.Approved, Investigational
BupranololBupranolol may decrease the bronchodilatory activities of Theophylline.Approved
BupropionThe metabolism of Theophylline can be decreased when combined with Bupropion.Approved
CaffeineThe metabolism of Theophylline can be decreased when combined with Caffeine.Approved
CamazepamThe therapeutic efficacy of Camazepam can be decreased when used in combination with Theophylline.Approved, Illicit
CandoxatrilThe serum concentration of Theophylline can be decreased when it is combined with Candoxatril.Experimental
CandoxatrilatThe serum concentration of Theophylline can be decreased when it is combined with Candoxatrilat.Experimental
CapecitabineThe metabolism of Theophylline can be decreased when combined with Capecitabine.Approved, Investigational
CaptoprilThe serum concentration of Theophylline can be decreased when it is combined with Captopril.Approved
CarbamazepineThe serum concentration of Theophylline can be decreased when it is combined with Carbamazepine.Approved, Investigational
CarbimazoleThe serum concentration of Theophylline can be increased when it is combined with Carbimazole.Approved
CarbomycinThe metabolism of Theophylline can be decreased when combined with Carbomycin.Vet Approved
CarmustineThe metabolism of Carmustine can be decreased when combined with Theophylline.Approved
CarteololCarteolol may decrease the bronchodilatory activities of Theophylline.Approved
CarvedilolThe metabolism of Carvedilol can be decreased when combined with Theophylline.Approved, Investigational
CelecoxibThe metabolism of Theophylline can be decreased when combined with Celecoxib.Approved, Investigational
CeliprololCeliprolol may decrease the bronchodilatory activities of Theophylline.Approved, Investigational
CeritinibThe serum concentration of Theophylline can be increased when it is combined with Ceritinib.Approved
ChlordiazepoxideThe therapeutic efficacy of Chlordiazepoxide can be decreased when used in combination with Theophylline.Approved, Illicit
ChloroquineThe metabolism of Theophylline can be decreased when combined with Chloroquine.Approved, Vet Approved
ChlorotrianiseneThe serum concentration of Theophylline can be increased when it is combined with Chlorotrianisene.Withdrawn
ChlorpromazineThe metabolism of Chlorpromazine can be decreased when combined with Theophylline.Approved, Vet Approved
ChlorzoxazoneThe metabolism of Chlorzoxazone can be decreased when combined with Theophylline.Approved
CholecalciferolThe metabolism of Theophylline can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
ChymostatinThe serum concentration of Theophylline can be decreased when it is combined with Chymostatin.Experimental
CilastatinThe serum concentration of Theophylline can be decreased when it is combined with Cilastatin.Approved
CilazaprilThe serum concentration of Theophylline can be decreased when it is combined with Cilazapril.Approved
CilostazolThe metabolism of Cilostazol can be decreased when combined with Theophylline.Approved
CimetidineThe metabolism of Theophylline can be decreased when combined with Cimetidine.Approved
CinacalcetThe metabolism of Theophylline can be decreased when combined with Cinacalcet.Approved
CinnarizineThe metabolism of Cinnarizine can be decreased when combined with Theophylline.Approved
CinoxacinThe metabolism of Theophylline can be decreased when combined with Cinoxacin.Approved, Withdrawn
CiprofloxacinThe metabolism of Theophylline can be decreased when combined with Ciprofloxacin.Approved, Investigational
CisaprideThe metabolism of Cisapride can be decreased when combined with Theophylline.Approved, Investigational, Withdrawn
CitalopramThe metabolism of Theophylline can be decreased when combined with Citalopram.Approved
ClarithromycinThe metabolism of Theophylline can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Theophylline can be decreased when combined with Clemastine.Approved
ClenbuterolThe metabolism of Clenbuterol can be decreased when combined with Theophylline.Approved, Vet Approved
ClevidipineThe metabolism of Clevidipine can be decreased when combined with Theophylline.Approved
ClobazamThe metabolism of Theophylline can be decreased when combined with Clobazam.Approved, Illicit
ClomipramineThe metabolism of Clomipramine can be decreased when combined with Theophylline.Approved, Vet Approved
ClonazepamThe therapeutic efficacy of Clonazepam can be decreased when used in combination with Theophylline.Approved, Illicit
ClonidineThe metabolism of Clonidine can be decreased when combined with Theophylline.Approved
ClopidogrelThe metabolism of Theophylline can be decreased when combined with Clopidogrel.Approved, Nutraceutical
ClorazepateThe therapeutic efficacy of Clorazepate can be decreased when used in combination with Theophylline.Approved, Illicit
ClotrimazoleThe metabolism of Theophylline can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe metabolism of Clozapine can be decreased when combined with Theophylline.Approved
CobicistatThe serum concentration of Theophylline can be increased when it is combined with Cobicistat.Approved
CocaineThe metabolism of Theophylline can be decreased when combined with Cocaine.Approved, Illicit
ConivaptanThe serum concentration of Theophylline can be increased when it is combined with Conivaptan.Approved, Investigational
Conjugated Equine EstrogensThe metabolism of Conjugated Equine Estrogens can be decreased when combined with Theophylline.Approved
CrizotinibThe metabolism of Theophylline can be decreased when combined with Crizotinib.Approved
CyclobenzaprineThe metabolism of Cyclobenzaprine can be decreased when combined with Theophylline.Approved
CyclosporineThe metabolism of Theophylline can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
Cyproterone acetateThe serum concentration of Theophylline can be decreased when it is combined with Cyproterone acetate.Approved, Investigational
Dabigatran etexilateThe serum concentration of Theophylline can be decreased when it is combined with Dabigatran etexilate.Approved
DabrafenibThe serum concentration of Theophylline can be decreased when it is combined with Dabrafenib.Approved
DacarbazineThe metabolism of Dacarbazine can be decreased when combined with Theophylline.Approved, Investigational
DapagliflozinThe metabolism of Dapagliflozin can be decreased when combined with Theophylline.Approved
DarifenacinThe metabolism of Theophylline can be decreased when combined with Darifenacin.Approved, Investigational
DarunavirThe serum concentration of Theophylline can be increased when it is combined with Darunavir.Approved
DasatinibThe serum concentration of Theophylline can be increased when it is combined with Dasatinib.Approved, Investigational
DaunorubicinThe metabolism of Daunorubicin can be decreased when combined with Theophylline.Approved
DeferasiroxThe serum concentration of Theophylline can be increased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Theophylline can be decreased when combined with Delavirdine.Approved
DelorazepamThe therapeutic efficacy of Delorazepam can be decreased when used in combination with Theophylline.Approved, Illicit
DesipramineThe metabolism of Desipramine can be decreased when combined with Theophylline.Approved
DexamethasoneThe serum concentration of Theophylline can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DexfenfluramineThe metabolism of Dexfenfluramine can be decreased when combined with Theophylline.Approved, Illicit, Withdrawn
DiazepamThe therapeutic efficacy of Diazepam can be decreased when used in combination with Theophylline.Approved, Illicit, Vet Approved
DiclofenacThe metabolism of Diclofenac can be decreased when combined with Theophylline.Approved, Vet Approved
DienestrolThe serum concentration of Theophylline can be increased when it is combined with Dienestrol.Approved
DiethylstilbestrolThe serum concentration of Theophylline can be increased when it is combined with Diethylstilbestrol.Approved
DihydroergotamineThe metabolism of Theophylline can be decreased when combined with Dihydroergotamine.Approved
DiltiazemThe metabolism of Theophylline can be decreased when combined with Diltiazem.Approved
DinoprostoneThe metabolism of Dinoprostone can be decreased when combined with Theophylline.Approved
DiphenhydramineThe metabolism of Diphenhydramine can be decreased when combined with Theophylline.Approved
DisulfiramThe serum concentration of Theophylline can be increased when it is combined with Disulfiram.Approved
DomperidoneThe metabolism of Domperidone can be decreased when combined with Theophylline.Approved, Investigational, Vet Approved
DoxepinThe metabolism of Doxepin can be decreased when combined with Theophylline.Approved
DoxofyllineThe risk or severity of adverse effects can be increased when Theophylline is combined with Doxofylline.Approved
DoxycyclineThe metabolism of Theophylline can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronedaroneThe metabolism of Theophylline can be decreased when combined with Dronedarone.Approved
DuloxetineThe metabolism of Duloxetine can be decreased when combined with Theophylline.Approved
EcabetThe serum concentration of Theophylline can be decreased when it is combined with Ecabet.Approved, Investigational
EdoxabanThe serum concentration of Theophylline can be decreased when it is combined with Edoxaban.Approved
EfavirenzThe serum concentration of Theophylline can be decreased when it is combined with Efavirenz.Approved, Investigational
ElafinThe serum concentration of Theophylline can be decreased when it is combined with Elafin.Investigational
EliglustatThe metabolism of Theophylline can be decreased when combined with Eliglustat.Approved
EltrombopagThe metabolism of Eltrombopag can be decreased when combined with Theophylline.Approved
EnalaprilThe serum concentration of Theophylline can be decreased when it is combined with Enalapril.Approved, Vet Approved
EnalaprilatThe serum concentration of Theophylline can be decreased when it is combined with Enalaprilat.Approved
EnalkirenThe serum concentration of Theophylline can be decreased when it is combined with Enalkiren.Experimental
EnoxacinThe metabolism of Theophylline can be decreased when combined with Enoxacin.Approved
EnzalutamideThe serum concentration of Theophylline can be decreased when it is combined with Enzalutamide.Approved
ErgotamineThe metabolism of Ergotamine can be decreased when combined with Theophylline.Approved
ErlotinibThe metabolism of Erlotinib can be decreased when combined with Theophylline.Approved, Investigational
ErythromycinThe metabolism of Theophylline can be decreased when combined with Erythromycin.Approved, Vet Approved
Eslicarbazepine acetateThe serum concentration of Theophylline can be decreased when it is combined with Eslicarbazepine acetate.Approved
EsmololEsmolol may decrease the bronchodilatory activities of Theophylline.Approved
EstazolamThe therapeutic efficacy of Estazolam can be decreased when used in combination with Theophylline.Approved, Illicit
EstradiolThe metabolism of Estradiol can be decreased when combined with Theophylline.Approved, Investigational, Vet Approved
EstriolThe serum concentration of Theophylline can be increased when it is combined with Estriol.Approved, Vet Approved
EstroneThe metabolism of Estrone can be decreased when combined with Theophylline.Approved
Estrone sulfateThe metabolism of Estrone sulfate can be decreased when combined with Theophylline.Approved
EthanolThe serum concentration of Theophylline can be increased when it is combined with Ethanol.Approved
Ethinyl EstradiolThe serum concentration of Theophylline can be increased when it is combined with Ethinyl Estradiol.Approved
EtizolamThe therapeutic efficacy of Etizolam can be decreased when used in combination with Theophylline.Approved
EtoposideThe metabolism of Etoposide can be decreased when combined with Theophylline.Approved
EtoricoxibThe metabolism of Etoricoxib can be decreased when combined with Theophylline.Approved, Investigational
EtravirineThe serum concentration of Theophylline can be decreased when it is combined with Etravirine.Approved
FebuxostatThe serum concentration of the active metabolites of Theophylline can be increased when Theophylline is used in combination with Febuxostat.Approved
FelodipineThe metabolism of Theophylline can be decreased when combined with Felodipine.Approved, Investigational
FleroxacinThe metabolism of Theophylline can be decreased when combined with Fleroxacin.Approved
FloxuridineThe metabolism of Theophylline can be decreased when combined with Floxuridine.Approved
FluconazoleThe metabolism of Theophylline can be decreased when combined with Fluconazole.Approved
FludiazepamThe therapeutic efficacy of Fludiazepam can be decreased when used in combination with Theophylline.Approved, Illicit
FlumazenilThe therapeutic efficacy of Flumazenil can be decreased when used in combination with Theophylline.Approved
FlumequineThe metabolism of Theophylline can be decreased when combined with Flumequine.Withdrawn
FlunarizineThe metabolism of Flunarizine can be decreased when combined with Theophylline.Approved
FlunitrazepamThe therapeutic efficacy of Flunitrazepam can be decreased when used in combination with Theophylline.Approved, Illicit
FluorouracilThe metabolism of Theophylline can be decreased when combined with Fluorouracil.Approved
FluoxetineThe metabolism of Theophylline can be decreased when combined with Fluoxetine.Approved, Vet Approved
FlurazepamThe therapeutic efficacy of Flurazepam can be decreased when used in combination with Theophylline.Approved, Illicit
FlutamideThe metabolism of Flutamide can be decreased when combined with Theophylline.Approved
FluvastatinThe metabolism of Theophylline can be decreased when combined with Fluvastatin.Approved
FluvoxamineThe metabolism of Theophylline can be decreased when combined with Fluvoxamine.Approved, Investigational
FormoterolThe risk or severity of adverse effects can be increased when Theophylline is combined with Formoterol.Approved, Investigational
FosamprenavirThe metabolism of Theophylline can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Theophylline can be increased when it is combined with Fosaprepitant.Approved
FosinoprilThe serum concentration of Theophylline can be decreased when it is combined with Fosinopril.Approved
FosphenytoinThe serum concentration of Theophylline can be decreased when it is combined with Fosphenytoin.Approved
FrovatriptanThe metabolism of Frovatriptan can be decreased when combined with Theophylline.Approved, Investigational
Fusidic AcidThe serum concentration of Theophylline can be increased when it is combined with Fusidic Acid.Approved
GabexateThe serum concentration of Theophylline can be decreased when it is combined with Gabexate.Investigational
GarenoxacinThe metabolism of Theophylline can be decreased when combined with Garenoxacin.Investigational
GatifloxacinThe metabolism of Theophylline can be decreased when combined with Gatifloxacin.Approved, Investigational
GeldanamycinThe serum concentration of Theophylline can be decreased when it is combined with Geldanamycin.Experimental
GemfibrozilThe metabolism of Theophylline can be decreased when combined with Gemfibrozil.Approved
GemifloxacinThe metabolism of Theophylline can be decreased when combined with Gemifloxacin.Approved, Investigational
GenisteinThe metabolism of Genistein can be decreased when combined with Theophylline.Investigational
GM6001The serum concentration of Theophylline can be decreased when it is combined with GM6001.Experimental
GrepafloxacinThe metabolism of Theophylline can be decreased when combined with Grepafloxacin.Withdrawn
GuanabenzThe metabolism of Guanabenz can be decreased when combined with Theophylline.Approved
HaloperidolThe metabolism of Haloperidol can be decreased when combined with Theophylline.Approved
HesperetinThe metabolism of Hesperetin can be decreased when combined with Theophylline.Approved
HexestrolThe serum concentration of Theophylline can be increased when it is combined with Hexestrol.Withdrawn
HexobarbitalThe metabolism of Hexobarbital can be decreased when combined with Theophylline.Approved
HirulogThe serum concentration of Theophylline can be decreased when it is combined with Hirulog.Experimental
IdelalisibThe serum concentration of Theophylline can be increased when it is combined with Idelalisib.Approved
idraparinuxThe serum concentration of Theophylline can be decreased when it is combined with idraparinux.Investigational
IFNaThe metabolism of Theophylline can be decreased when combined with IFNa.Investigational
IloperidoneThe metabolism of Iloperidone can be decreased when combined with Theophylline.Approved
ImatinibThe metabolism of Theophylline can be decreased when combined with Imatinib.Approved
ImidaprilThe serum concentration of Theophylline can be decreased when it is combined with Imidapril.Investigational
ImipramineThe metabolism of Imipramine can be decreased when combined with Theophylline.Approved
ImiquimodThe metabolism of Imiquimod can be decreased when combined with Theophylline.Approved, Investigational
IndacaterolThe risk or severity of adverse effects can be increased when Theophylline is combined with Indacaterol.Approved
IndinavirThe metabolism of Theophylline can be decreased when combined with Indinavir.Approved
Interferon Alfa-2a, RecombinantThe metabolism of Theophylline can be decreased when combined with Interferon Alfa-2a, Recombinant.Approved
Interferon Alfa-2b, RecombinantThe metabolism of Theophylline can be decreased when combined with Interferon Alfa-2b, Recombinant.Approved
Interferon alfa-n1The metabolism of Theophylline can be decreased when combined with Interferon alfa-n1.Approved
Interferon alfa-n3The metabolism of Theophylline can be decreased when combined with Interferon alfa-n3.Approved, Investigational
Interferon alfacon-1The metabolism of Theophylline can be decreased when combined with Interferon alfacon-1.Approved
Interferon beta-1aThe metabolism of Theophylline can be decreased when combined with Interferon beta-1a.Approved, Investigational
Interferon beta-1bThe metabolism of Theophylline can be decreased when combined with Interferon beta-1b.Approved
Interferon gamma-1bThe metabolism of Theophylline can be decreased when combined with Interferon gamma-1b.Approved, Investigational
IrbesartanThe metabolism of Theophylline can be decreased when combined with Irbesartan.Approved, Investigational
IsavuconazoniumThe metabolism of Theophylline can be decreased when combined with Isavuconazonium.Approved, Investigational
IsoflurophateThe serum concentration of Theophylline can be decreased when it is combined with Isoflurophate.Approved, Withdrawn
IsoniazidThe serum concentration of Theophylline can be increased when it is combined with Isoniazid.Approved
IsoprenalineThe serum concentration of Theophylline can be decreased when it is combined with Isoprenaline.Approved
IsradipineThe metabolism of Theophylline can be decreased when combined with Isradipine.Approved
ItraconazoleThe metabolism of Theophylline can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Theophylline can be increased when it is combined with Ivacaftor.Approved
IxazomibThe metabolism of Ixazomib can be decreased when combined with Theophylline.Approved
JosamycinThe metabolism of Theophylline can be decreased when combined with Josamycin.Approved
KetoconazoleThe metabolism of Theophylline can be decreased when combined with Ketoconazole.Approved, Investigational
KitasamycinThe metabolism of Theophylline can be decreased when combined with Kitasamycin.Experimental
LapatinibThe metabolism of Theophylline can be decreased when combined with Lapatinib.Approved, Investigational
LeflunomideThe metabolism of Leflunomide can be decreased when combined with Theophylline.Approved, Investigational
LepirudinThe serum concentration of Theophylline can be decreased when it is combined with Lepirudin.Approved
LevobupivacaineThe metabolism of Levobupivacaine can be decreased when combined with Theophylline.Approved
LevofloxacinThe metabolism of Theophylline can be decreased when combined with Levofloxacin.Approved, Investigational
LevothyroxineThe metabolism of Theophylline can be increased when combined with Levothyroxine.Approved
LidocaineThe metabolism of Lidocaine can be decreased when combined with Theophylline.Approved, Vet Approved
LinagliptinThe serum concentration of Theophylline can be decreased when it is combined with Linagliptin.Approved
LiothyronineThe metabolism of Theophylline can be increased when combined with Liothyronine.Approved, Vet Approved
LiotrixThe metabolism of Theophylline can be increased when combined with Liotrix.Approved
LisinoprilThe serum concentration of Theophylline can be decreased when it is combined with Lisinopril.Approved, Investigational
LithiumThe serum concentration of Lithium can be decreased when it is combined with Theophylline.Approved
LomefloxacinThe metabolism of Theophylline can be decreased when combined with Lomefloxacin.Approved
LopinavirThe metabolism of Theophylline can be decreased when combined with Lopinavir.Approved
LorazepamThe therapeutic efficacy of Lorazepam can be decreased when used in combination with Theophylline.Approved
LorcaserinThe metabolism of Lorcaserin can be decreased when combined with Theophylline.Approved
LosartanThe metabolism of Theophylline can be decreased when combined with Losartan.Approved
LovastatinThe metabolism of Theophylline can be decreased when combined with Lovastatin.Approved, Investigational
LuliconazoleThe serum concentration of Theophylline can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Theophylline can be increased when it is combined with Lumacaftor.Approved
LumefantrineThe metabolism of Theophylline can be decreased when combined with Lumefantrine.Approved
LumiracoxibThe metabolism of Lumiracoxib can be decreased when combined with Theophylline.Approved, Investigational
MalathionThe metabolism of Malathion can be decreased when combined with Theophylline.Approved, Investigational
MaprotilineThe metabolism of Maprotiline can be decreased when combined with Theophylline.Approved
MelatoninThe metabolism of Melatonin can be decreased when combined with Theophylline.Approved, Nutraceutical, Vet Approved
MenadioneThe metabolism of Menadione can be decreased when combined with Theophylline.Approved, Nutraceutical
MephenytoinThe metabolism of Mephenytoin can be decreased when combined with Theophylline.Investigational, Withdrawn
MestranolThe serum concentration of Theophylline can be increased when it is combined with Mestranol.Approved
MethadoneThe metabolism of Methadone can be decreased when combined with Theophylline.Approved
MethallenestrilThe serum concentration of Theophylline can be increased when it is combined with Methallenestril.Experimental
MethimazoleThe serum concentration of Theophylline can be increased when it is combined with Methimazole.Approved
MethohexitalThe serum concentration of Theophylline can be decreased when it is combined with Methohexital.Approved
MethotrexateThe serum concentration of Theophylline can be increased when it is combined with Methotrexate.Approved
MethotrimeprazineThe metabolism of Theophylline can be decreased when combined with Methotrimeprazine.Approved
MethoxyfluraneThe metabolism of Methoxyflurane can be decreased when combined with Theophylline.Approved, Vet Approved
MethylphenobarbitalThe serum concentration of Theophylline can be decreased when it is combined with Methylphenobarbital.Approved
MetoprololThe metabolism of Theophylline can be decreased when combined with Metoprolol.Approved, Investigational
MetreleptinThe serum concentration of Theophylline can be decreased when it is combined with Metreleptin.Approved
MexiletineThe metabolism of Theophylline can be decreased when combined with Mexiletine.Approved
MianserinThe metabolism of Mianserin can be decreased when combined with Theophylline.Approved
MidazolamThe therapeutic efficacy of Midazolam can be decreased when used in combination with Theophylline.Approved, Illicit
MifepristoneThe serum concentration of Theophylline can be increased when it is combined with Mifepristone.Approved, Investigational
MirabegronThe metabolism of Theophylline can be decreased when combined with Mirabegron.Approved
MirtazapineThe metabolism of Mirtazapine can be decreased when combined with Theophylline.Approved
MitotaneThe serum concentration of Theophylline can be decreased when it is combined with Mitotane.Approved
ModafinilThe serum concentration of Theophylline can be decreased when it is combined with Modafinil.Approved, Investigational
MoexiprilThe serum concentration of Theophylline can be decreased when it is combined with Moexipril.Approved
MoxifloxacinThe metabolism of Theophylline can be decreased when combined with Moxifloxacin.Approved, Investigational
muraglitazarThe metabolism of muraglitazar can be decreased when combined with Theophylline.Investigational
N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-ProlineThe serum concentration of Theophylline can be decreased when it is combined with N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-Proline.Experimental
NabumetoneThe metabolism of Nabumetone can be decreased when combined with Theophylline.Approved
NadololNadolol may decrease the bronchodilatory activities of Theophylline.Approved
NafamostatThe serum concentration of Theophylline can be decreased when it is combined with Nafamostat.Investigational
NafcillinThe serum concentration of Theophylline can be decreased when it is combined with Nafcillin.Approved
Nalidixic AcidThe metabolism of Theophylline can be decreased when combined with Nalidixic Acid.Approved
NaproxenThe metabolism of Naproxen can be decreased when combined with Theophylline.Approved, Vet Approved
Natural alpha interferonThe metabolism of Theophylline can be decreased when combined with Natural alpha interferon.Approved, Investigational
NCX 4016The serum concentration of Theophylline can be decreased when it is combined with NCX 4016.Investigational
NebivololNebivolol may decrease the bronchodilatory activities of Theophylline.Approved, Investigational
NefazodoneThe metabolism of Theophylline can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Theophylline can be decreased when combined with Nelfinavir.Approved
NemonoxacinThe metabolism of Theophylline can be decreased when combined with Nemonoxacin.Investigational
NetazepideThe therapeutic efficacy of Netazepide can be decreased when used in combination with Theophylline.Investigational
NetupitantThe serum concentration of Theophylline can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Theophylline can be increased when combined with Nevirapine.Approved
NicardipineThe metabolism of Theophylline can be decreased when combined with Nicardipine.Approved
NicotineThe metabolism of Nicotine can be decreased when combined with Theophylline.Approved
NifedipineThe metabolism of Nifedipine can be decreased when combined with Theophylline.Approved
NilotinibThe metabolism of Theophylline can be decreased when combined with Nilotinib.Approved, Investigational
NitrazepamThe therapeutic efficacy of Nitrazepam can be decreased when used in combination with Theophylline.Approved
Nitric OxideThe metabolism of Nitric Oxide can be decreased when combined with Theophylline.Approved
NitroaspirinThe serum concentration of Theophylline can be decreased when it is combined with Nitroaspirin.Investigational
NorfloxacinThe metabolism of Theophylline can be decreased when combined with Norfloxacin.Approved
NortriptylineThe metabolism of Nortriptyline can be decreased when combined with Theophylline.Approved
OfloxacinThe metabolism of Theophylline can be decreased when combined with Ofloxacin.Approved
OlanzapineThe metabolism of Olanzapine can be decreased when combined with Theophylline.Approved, Investigational
OlaparibThe metabolism of Theophylline can be decreased when combined with Olaparib.Approved
OleandomycinThe metabolism of Theophylline can be decreased when combined with Oleandomycin.Vet Approved
OlodaterolThe risk or severity of adverse effects can be increased when Theophylline is combined with Olodaterol.Approved
OmapatrilatThe serum concentration of Theophylline can be decreased when it is combined with Omapatrilat.Investigational
OmeprazoleThe metabolism of Omeprazole can be decreased when combined with Theophylline.Approved, Investigational, Vet Approved
OndansetronThe metabolism of Ondansetron can be decreased when combined with Theophylline.Approved
OsimertinibThe serum concentration of Theophylline can be increased when it is combined with Osimertinib.Approved
OtamixabanThe serum concentration of Theophylline can be decreased when it is combined with Otamixaban.Investigational
OxaliplatinThe metabolism of Oxaliplatin can be decreased when combined with Theophylline.Approved, Investigational
OxazepamThe therapeutic efficacy of Oxazepam can be decreased when used in combination with Theophylline.Approved
OxprenololOxprenolol may decrease the bronchodilatory activities of Theophylline.Approved
OxtriphyllineThe metabolism of Oxtriphylline can be decreased when combined with Theophylline.Approved
PalbociclibThe serum concentration of Theophylline can be increased when it is combined with Palbociclib.Approved
PalonosetronThe metabolism of Palonosetron can be decreased when combined with Theophylline.Approved, Investigational
PancuroniumThe risk or severity of adverse effects can be increased when Theophylline is combined with Pancuronium.Approved
PanobinostatThe serum concentration of Theophylline can be increased when it is combined with Panobinostat.Approved, Investigational
PantoprazoleThe metabolism of Pantoprazole can be decreased when combined with Theophylline.Approved
ParoxetineThe metabolism of Theophylline can be decreased when combined with Paroxetine.Approved, Investigational
PazopanibThe metabolism of Pazopanib can be decreased when combined with Theophylline.Approved
PazufloxacinThe metabolism of Theophylline can be decreased when combined with Pazufloxacin.Investigational
PefloxacinThe metabolism of Theophylline can be decreased when combined with Pefloxacin.Approved
Peginterferon alfa-2aThe metabolism of Theophylline can be decreased when combined with Peginterferon alfa-2a.Approved, Investigational
Peginterferon alfa-2bThe serum concentration of Theophylline can be decreased when it is combined with Peginterferon alfa-2b.Approved
Peginterferon beta-1aThe metabolism of Theophylline can be decreased when combined with Peginterferon beta-1a.Approved
PenbutololPenbutolol may decrease the bronchodilatory activities of Theophylline.Approved, Investigational
PentamidineThe metabolism of Pentamidine can be decreased when combined with Theophylline.Approved
PentobarbitalThe metabolism of Theophylline can be increased when combined with Pentobarbital.Approved, Vet Approved
PentoxifyllineThe serum concentration of Theophylline can be increased when it is combined with Pentoxifylline.Approved, Investigational
PerindoprilThe serum concentration of Theophylline can be decreased when it is combined with Perindopril.Approved
PerphenazineThe metabolism of Perphenazine can be decreased when combined with Theophylline.Approved
Pf 00477736The therapeutic efficacy of Pf 00477736 can be decreased when used in combination with Theophylline.Investigational
PhenacetinThe metabolism of Phenacetin can be decreased when combined with Theophylline.Withdrawn
PhenobarbitalThe metabolism of Theophylline can be increased when combined with Phenobarbital.Approved
PhenytoinThe serum concentration of Theophylline can be decreased when it is combined with Phenytoin.Approved, Vet Approved
PhosphoramidonThe serum concentration of Theophylline can be decreased when it is combined with Phosphoramidon.Experimental
PimozideThe metabolism of Pimozide can be decreased when combined with Theophylline.Approved
PindololPindolol may decrease the bronchodilatory activities of Theophylline.Approved
PioglitazoneThe metabolism of Theophylline can be decreased when combined with Pioglitazone.Approved, Investigational
PipotiazineThe metabolism of Pipotiazine can be decreased when combined with Theophylline.Approved
PirenzepineThe therapeutic efficacy of Pirenzepine can be decreased when used in combination with Theophylline.Approved
PirfenidoneThe serum concentration of Pirfenidone can be increased when it is combined with Theophylline.Investigational
Polyestradiol phosphateThe serum concentration of Theophylline can be increased when it is combined with Polyestradiol phosphate.Approved
PomalidomideThe metabolism of Pomalidomide can be decreased when combined with Theophylline.Approved
PosaconazoleThe metabolism of Theophylline can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PrazepamThe therapeutic efficacy of Prazepam can be decreased when used in combination with Theophylline.Approved, Illicit
PraziquantelThe metabolism of Praziquantel can be decreased when combined with Theophylline.Approved, Vet Approved
PrimaquineThe metabolism of Primaquine can be decreased when combined with Theophylline.Approved
PrimidoneThe metabolism of Theophylline can be increased when combined with Primidone.Approved, Vet Approved
PrinomastatThe serum concentration of Theophylline can be decreased when it is combined with Prinomastat.Investigational
ProbenecidThe serum concentration of Theophylline can be increased when it is combined with Probenecid.Approved
ProgesteroneThe metabolism of Progesterone can be decreased when combined with Theophylline.Approved, Vet Approved
ProguanilThe metabolism of Proguanil can be decreased when combined with Theophylline.Approved
PromazineThe metabolism of Promazine can be decreased when combined with Theophylline.Approved, Vet Approved
PromestrieneThe serum concentration of Theophylline can be increased when it is combined with Promestriene.Investigational
PropafenoneThe serum concentration of Theophylline can be increased when it is combined with Propafenone.Approved
PropofolThe metabolism of Propofol can be decreased when combined with Theophylline.Approved, Investigational, Vet Approved
PropranololPropranolol may decrease the bronchodilatory activities of Theophylline.Approved, Investigational
PropylthiouracilThe serum concentration of Theophylline can be increased when it is combined with Propylthiouracil.Approved
PrulifloxacinThe metabolism of Theophylline can be decreased when combined with Prulifloxacin.Investigational
PyrazinamideThe metabolism of Pyrazinamide can be decreased when combined with Theophylline.Approved
PyrimethamineThe metabolism of Theophylline can be decreased when combined with Pyrimethamine.Approved, Vet Approved
QuinaprilThe serum concentration of Theophylline can be decreased when it is combined with Quinapril.Approved, Investigational
QuinestrolThe serum concentration of Theophylline can be increased when it is combined with Quinestrol.Approved
QuinidineThe metabolism of Theophylline can be decreased when combined with Quinidine.Approved
QuinineThe serum concentration of Theophylline can be increased when it is combined with Quinine.Approved
RabeprazoleThe metabolism of Theophylline can be decreased when combined with Rabeprazole.Approved, Investigational
RacecadotrilThe serum concentration of Theophylline can be decreased when it is combined with Racecadotril.Investigational
RamelteonThe metabolism of Ramelteon can be decreased when combined with Theophylline.Approved, Investigational
RamiprilThe serum concentration of Theophylline can be decreased when it is combined with Ramipril.Approved
RanitidineThe metabolism of Ranitidine can be decreased when combined with Theophylline.Approved
RanolazineThe metabolism of Theophylline can be decreased when combined with Ranolazine.Approved, Investigational
RasagilineThe metabolism of Rasagiline can be decreased when combined with Theophylline.Approved
RegadenosonTheophylline may decrease the vasodilatory activities of Regadenoson.Approved
RemikirenThe serum concentration of Theophylline can be decreased when it is combined with Remikiren.Approved
ResveratrolThe metabolism of Resveratrol can be decreased when combined with Theophylline.Experimental, Investigational
RifabutinThe metabolism of Theophylline can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Theophylline can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Theophylline can be increased when combined with Rifapentine.Approved
RiluzoleThe metabolism of Riluzole can be decreased when combined with Theophylline.Approved, Investigational
RiociguatTheophylline may increase the hypotensive activities of Riociguat.Approved
RitonavirThe metabolism of Theophylline can be decreased when combined with Ritonavir.Approved, Investigational
RivaroxabanThe serum concentration of Theophylline can be decreased when it is combined with Rivaroxaban.Approved
RizatriptanThe metabolism of Rizatriptan can be decreased when combined with Theophylline.Approved
RofecoxibThe metabolism of Rofecoxib can be decreased when combined with Theophylline.Investigational, Withdrawn
RolapitantThe metabolism of Theophylline can be decreased when combined with Rolapitant.Approved
RopiniroleThe metabolism of Theophylline can be decreased when combined with Ropinirole.Approved, Investigational
RopivacaineThe metabolism of Ropivacaine can be decreased when combined with Theophylline.Approved
RosiglitazoneThe metabolism of Theophylline can be decreased when combined with Rosiglitazone.Approved, Investigational
RosoxacinThe metabolism of Theophylline can be decreased when combined with Rosoxacin.Approved
RotigotineThe metabolism of Rotigotine can be decreased when combined with Theophylline.Approved
S EquolThe serum concentration of Theophylline can be increased when it is combined with S Equol.Investigational
SaquinavirThe metabolism of Theophylline can be decreased when combined with Saquinavir.Approved, Investigational
SaxagliptinThe serum concentration of Theophylline can be decreased when it is combined with Saxagliptin.Approved
SecobarbitalThe metabolism of Theophylline can be increased when combined with Secobarbital.Approved, Vet Approved
SecoisolariciresinolThe serum concentration of Theophylline can be increased when it is combined with Secoisolariciresinol.Investigational
SelegilineThe metabolism of Selegiline can be decreased when combined with Theophylline.Approved, Investigational, Vet Approved
SertralineThe metabolism of Sertraline can be decreased when combined with Theophylline.Approved
SildenafilThe metabolism of Theophylline can be decreased when combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Theophylline can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Theophylline can be increased when it is combined with Simeprevir.Approved
SitagliptinThe serum concentration of Theophylline can be decreased when it is combined with Sitagliptin.Approved, Investigational
SolithromycinThe metabolism of Theophylline can be decreased when combined with Solithromycin.Investigational
SorafenibThe metabolism of Theophylline can be decreased when combined with Sorafenib.Approved, Investigational
SotalolSotalol may decrease the bronchodilatory activities of Theophylline.Approved
SparfloxacinThe metabolism of Theophylline can be decreased when combined with Sparfloxacin.Approved
SpiraprilThe serum concentration of Theophylline can be decreased when it is combined with Spirapril.Approved
St. John's WortThe serum concentration of Theophylline can be decreased when it is combined with St. John's Wort.Nutraceutical
StiripentolThe serum concentration of Theophylline can be increased when it is combined with Stiripentol.Approved
SulfadiazineThe metabolism of Theophylline can be decreased when combined with Sulfadiazine.Approved, Vet Approved
SulfamethoxazoleThe metabolism of Theophylline can be decreased when combined with Sulfamethoxazole.Approved
SulfisoxazoleThe metabolism of Theophylline can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
Synthetic Conjugated Estrogens, AThe serum concentration of Theophylline can be increased when it is combined with Synthetic Conjugated Estrogens, A.Approved
Synthetic Conjugated Estrogens, BThe serum concentration of Theophylline can be increased when it is combined with Synthetic Conjugated Estrogens, B.Approved
TacrineThe metabolism of Tacrine can be decreased when combined with Theophylline.Withdrawn
TamoxifenThe metabolism of Tamoxifen can be decreased when combined with Theophylline.Approved
TelaprevirThe metabolism of Theophylline can be decreased when combined with Telaprevir.Approved
TelithromycinThe metabolism of Theophylline can be decreased when combined with Telithromycin.Approved
TemafloxacinThe metabolism of Theophylline can be decreased when combined with Temafloxacin.Withdrawn
TemazepamThe therapeutic efficacy of Temazepam can be decreased when used in combination with Theophylline.Approved
TemocaprilThe serum concentration of Theophylline can be decreased when it is combined with Temocapril.Experimental, Investigational
TenofovirThe metabolism of Theophylline can be decreased when combined with Tenofovir.Approved, Investigational
TerbinafineThe metabolism of Theophylline can be decreased when combined with Terbinafine.Approved, Investigational, Vet Approved
TeriflunomideThe serum concentration of Theophylline can be decreased when it is combined with Teriflunomide.Approved
ThalidomideThe metabolism of Thalidomide can be decreased when combined with Theophylline.Approved, Investigational, Withdrawn
TheobromineThe metabolism of Theobromine can be decreased when combined with Theophylline.Approved
ThiabendazoleThe metabolism of Theophylline can be decreased when combined with Thiabendazole.Approved, Vet Approved
ThiamylalThe serum concentration of Theophylline can be decreased when it is combined with Thiamylal.Approved, Vet Approved
ThiopentalThe serum concentration of Theophylline can be decreased when it is combined with Thiopental.Approved, Vet Approved
ThioridazineThe metabolism of Theophylline can be decreased when combined with Thioridazine.Approved
ThiorphanThe serum concentration of Theophylline can be decreased when it is combined with Thiorphan.Experimental
ThiothixeneThe metabolism of Thiothixene can be decreased when combined with Theophylline.Approved
Thyroid, porcineThe metabolism of Theophylline can be increased when combined with Thyroid, porcine.Approved
TiboloneThe serum concentration of Theophylline can be increased when it is combined with Tibolone.Approved
TicagrelorThe metabolism of Theophylline can be decreased when combined with Ticagrelor.Approved
TiclopidineThe metabolism of Theophylline can be decreased when combined with Ticlopidine.Approved
TimololTimolol may decrease the bronchodilatory activities of Theophylline.Approved
TipranavirThe metabolism of Theophylline can be decreased when combined with Tipranavir.Approved, Investigational
TizanidineThe serum concentration of Tizanidine can be increased when it is combined with Theophylline.Approved
TocilizumabThe serum concentration of Theophylline can be decreased when it is combined with Tocilizumab.Approved
TolbutamideThe metabolism of Theophylline can be decreased when combined with Tolbutamide.Approved
ToremifeneThe metabolism of Toremifene can be decreased when combined with Theophylline.Approved, Investigational
TrandolaprilThe serum concentration of Theophylline can be decreased when it is combined with Trandolapril.Approved
TranylcypromineThe metabolism of Theophylline can be decreased when combined with Tranylcypromine.Approved
TriamtereneThe metabolism of Triamterene can be decreased when combined with Theophylline.Approved
TriazolamThe therapeutic efficacy of Triazolam can be decreased when used in combination with Theophylline.Approved
TrifluoperazineThe metabolism of Trifluoperazine can be decreased when combined with Theophylline.Approved
TrimethoprimThe metabolism of Theophylline can be decreased when combined with Trimethoprim.Approved, Vet Approved
TroleandomycinThe metabolism of Theophylline can be decreased when combined with Troleandomycin.Approved
TrovafloxacinThe metabolism of Theophylline can be decreased when combined with Trovafloxacin.Approved, Withdrawn
TylosinThe metabolism of Theophylline can be decreased when combined with Tylosin.Vet Approved
UbenimexThe serum concentration of Theophylline can be decreased when it is combined with Ubenimex.Experimental
UlinastatinThe serum concentration of Theophylline can be decreased when it is combined with Ulinastatin.Investigational
UlipristalThe metabolism of Ulipristal can be decreased when combined with Theophylline.Approved
Valproic AcidThe metabolism of Theophylline can be decreased when combined with Valproic Acid.Approved, Investigational
ValsartanThe metabolism of Theophylline can be decreased when combined with Valsartan.Approved, Investigational
VemurafenibThe serum concentration of Theophylline can be increased when it is combined with Vemurafenib.Approved
VenlafaxineThe metabolism of Theophylline can be decreased when combined with Venlafaxine.Approved
VerapamilThe metabolism of Theophylline can be decreased when combined with Verapamil.Approved
VildagliptinThe serum concentration of Theophylline can be decreased when it is combined with Vildagliptin.Approved, Investigational
VoriconazoleThe metabolism of Theophylline can be decreased when combined with Voriconazole.Approved, Investigational
WarfarinThe metabolism of Warfarin can be decreased when combined with Theophylline.Approved
XimelagatranThe serum concentration of Theophylline can be decreased when it is combined with Ximelagatran.Approved, Investigational, Withdrawn
Ym150The serum concentration of Theophylline can be decreased when it is combined with Ym150.Investigational
ZafirlukastThe serum concentration of Zafirlukast can be decreased when it is combined with Theophylline.Approved, Investigational
ZeranolThe serum concentration of Theophylline can be increased when it is combined with Zeranol.Vet Approved
ZileutonThe serum concentration of Theophylline can be increased when it is combined with Zileuton.Approved, Investigational, Withdrawn
ZiprasidoneThe metabolism of Theophylline can be decreased when combined with Ziprasidone.Approved
ZolmitriptanThe metabolism of Zolmitriptan can be decreased when combined with Theophylline.Approved, Investigational
ZolpidemThe metabolism of Zolpidem can be decreased when combined with Theophylline.Approved
Food Interactions
  • Avoid alcohol.
  • Avoid excessive quantities of coffee or tea (Caffeine).
  • Take with food.
References
Synthesis Reference

Nicolae S. Bodor, Kenneth B. Sloan, Yu-Neng Kuo, “Method for synthesizing certain selected pro-drug forms of theophylline.” U.S. Patent US4000132, issued January, 1956.

US4000132
General ReferencesNot Available
External Links
ATC CodesR03DA54R03DA74R03DA04R03DB04
AHFS Codes
  • 86:16.00
PDB EntriesNot Available
FDA labelDownload (85.2 KB)
MSDSDownload (75.1 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9902
Caco-2 permeable+0.6172
P-glycoprotein substrateNon-substrate0.7281
P-glycoprotein inhibitor INon-inhibitor0.8939
P-glycoprotein inhibitor IINon-inhibitor0.911
Renal organic cation transporterNon-inhibitor0.8807
CYP450 2C9 substrateNon-substrate0.7738
CYP450 2D6 substrateNon-substrate0.9117
CYP450 3A4 substrateNon-substrate0.5974
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.9933
CYP450 2D6 inhibitorNon-inhibitor0.9827
CYP450 2C19 inhibitorNon-inhibitor0.9895
CYP450 3A4 inhibitorNon-inhibitor0.9616
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9956
Ames testNon AMES toxic0.9132
CarcinogenicityNon-carcinogens0.9447
BiodegradationReady biodegradable0.5942
Rat acute toxicity2.7898 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8819
hERG inhibition (predictor II)Non-inhibitor0.8927
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Fleming and co pharmaceuticals inc
  • Forest laboratories inc
  • Sanofi aventis us llc
  • Dm graham laboratories inc
  • Ucb inc
  • Whitby pharmaceuticals inc
  • Schwarz pharma inc
  • Schering corp
  • Central pharmaceuticals inc
  • Hospira inc
  • Inwood laboratories inc sub forest laboratories inc
  • Sandoz inc
  • Rp scherer north america div rp scherer corp
  • Ortho mcneil pharmaceutical inc
  • Schering corp sub schering plough corp
  • Fisons corp
  • Kv pharmaceutical co
  • Rp scherer north america
  • Hr cenci laboratories inc
  • Caraco pharmaceutical laboratories ltd
  • Lannett co inc
  • Panray corp sub ormont drug and chemical co inc
  • Alpharma us pharmaceuticals division
  • Cenci powder products inc
  • Halsey drug co inc
  • L perrigo co
  • Pharmaceutical assoc inc div beach products
  • Precision dose inc
  • Roxane laboratories inc
  • Taro pharmaceuticals usa inc
  • Wockhardt eu operations (swiss) ag
  • B braun medical inc
  • Baxter healthcare corp
  • 3m pharmaceuticals inc
  • Ferndale laboratories inc
  • Warner chilcott co llc
  • Monarch pharmaceuticals inc
  • Roerig div pfizer inc
  • Able laboratories inc
  • Glenmark generics ltd
  • Nostrum pharmaceuticals inc
  • Pliva inc
  • Pharmaceutical research assoc inc
  • Purdue pharmaceutical products lp
  • Graceway pharmaceuticals llc
  • Novartis consumer health inc
Packagers
Dosage forms
FormRouteStrength
Tablet, extended releaseOral100 mg
Tablet, extended releaseOral200 mg
Tablet, extended releaseOral300 mg
LiquidOral80 mg/15mL
TabletOral
ElixirOral80 mg
SyrupOral
Kit
Capsule, extended releaseOral100 mg
Capsule, extended releaseOral200 mg
Capsule, extended releaseOral300 mg
Capsule, extended releaseOral50 mg
Capsule, extended releaseOral100 mg/1
Capsule, extended releaseOral200 mg/1
Capsule, extended releaseOral300 mg/1
Capsule, extended releaseOral400 mg/1
Tablet, extended releaseOral450 mg
LiquidOral80 mg
Tablet, extended releaseOral250 mg
Tablet, extended releaseOral500 mg
TabletOral125 mg
TabletOral250 mg
SolutionOral80 mg/15mL
Tablet, extended releaseOral100 mg/1
Tablet, extended releaseOral450 mg/1
Tablet, extended releaseOral600 mg/1
SolutionIntravenous
TabletOral300 mg/1
Tablet, extended releaseOral200 mg/1
Tablet, extended releaseOral300 mg/1
Injection, solutionIntravenous
Injection, solutionIntravenous160 mg/100mL
Injection, solutionIntravenous200 mg/100mL
Injection, solutionIntravenous320 mg/100mL
Injection, solutionIntravenous400 mg/100mL
Injection, solutionIntravenous80 mg/100mL
ElixirOral
Tablet, extended releaseOral400 mg/1
TabletOral400 mg/1
TabletOral600 mg/1
Tablet, extended releaseOral400 mg
Tablet, extended releaseOral600 mg
Prices
Unit descriptionCostUnit
Elixophyllin GG 100-100 mg/15ml Solution 240ml Bottle60.98USD bottle
Uniphyl 600 mg 24 Hour tablet2.28USD tablet
Theo-24 400 mg 24 Hour Capsule2.04USD capsule
Theo-24 400 mg capsule sa1.97USD capsule
Uniphyl 400 mg 24 Hour tablet1.58USD tablet
Theo-24 300 mg 24 Hour Capsule1.45USD capsule
Theo-24 300 mg capsule sa1.4USD capsule
Theophylline 400 mg 24 Hour tablet1.27USD tablet
Theo-24 200 mg 24 Hour Capsule1.25USD capsule
Theo-24 200 mg capsule sa1.14USD capsule
Theochron 450 mg tablet sa0.94USD tablet
Theophylline CR 300 mg 12 Hour Capsule0.93USD capsule
Theo-24 100 mg 24 Hour Capsule0.83USD capsule
Theophylline CR 200 mg 12 Hour Capsule0.79USD capsule
Theophylline CR 450 mg 12 Hour tablet0.79USD tablet
Theo-24 100 mg capsule sa0.76USD capsule
Quibron 90-150 mg capsule0.73USD capsule
Theophylline CR 125 mg 12 Hour Capsule0.73USD capsule
Uniphyl 600 mg Sustained-Release Tablet0.68USD tablet
Uniphyl 400 mg Sustained-Release Tablet0.56USD tablet
Theochron 300 mg tablet sa0.54USD tablet
Theophylline CR 300 mg 12 Hour tablet0.51USD tablet
Theophylline CR 200 mg 12 Hour tablet0.4USD tablet
Theochron 200 mg tablet sa0.33USD tablet
Theophylline CR 100 mg 12 Hour tablet0.3USD tablet
Elixophyllin GG 100-100 mg/15ml Solution0.24USD ml
Theochron 100 mg tablet sa0.23USD tablet
Elixophyllin 80 mg/15ml Elixir0.2USD ml
Elixophyllin 80 mg/15 ml elix0.19USD ml
Apo-Theo La 300 mg Sustained-Release Tablet0.15USD tablet
Apo-Theo La 100 mg Sustained-Release Tablet0.14USD tablet
Apo-Theo La 200 mg Sustained-Release Tablet0.14USD tablet
Theophylline anhydrous powder0.08USD g
Theophylline 200 mg/100 ml d5w0.06USD ml
Theolair 5.3 mg/ml Liquid0.03USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point273 °CPhysProp
water solubility7360 mg/L (at 25 °C)YALKOWSKY,SH & HE,Y (2003)
logP-0.02HANSCH,C ET AL. (1995)
Caco2 permeability-4.35ADME Research, USCD
pKa8.81KORTUM,G ET AL (1961)
Predicted Properties
PropertyValueSource
Water Solubility22.9 mg/mLALOGPS
logP-0.26ALOGPS
logP-0.77ChemAxon
logS-0.9ALOGPS
pKa (Strongest Acidic)7.82ChemAxon
pKa (Strongest Basic)-0.78ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area69.3 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity44.93 m3·mol-1ChemAxon
Polarizability16.86 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Download (2.96 KB)
Spectra
Spectrum TypeDescriptionSplash Key
GC-MSGC-MS Spectrum - GC-MS (1 TMS)splash10-0f79-6970000000-224461ad62a44dbdf860View in MoNA
LC-MS/MSLC-MS/MS Spectrum - Quattro_QQQ 10V, Positive (Annotated)splash10-00di-0900000000-0092516012d6a2a93b31View in MoNA
LC-MS/MSLC-MS/MS Spectrum - Quattro_QQQ 25V, Positive (Annotated)splash10-00di-4900000000-dcf52c18a6996f412b1aView in MoNA
LC-MS/MSLC-MS/MS Spectrum - Quattro_QQQ 40V, Positive (Annotated)splash10-00kf-9000000000-09089337909892ef44cbView in MoNA
LC-MS/MSLC-MS/MS Spectrum - EI-B (Unknown) , Positivesplash10-001j-7900000000-a08735d528e738752429View in MoNA
LC-MS/MSLC-MS/MS Spectrum - CI-B (Unknown) , Positivesplash10-001i-0900000000-d0882f7d959c726e7623View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 10V, Negativesplash10-004i-0900000000-c4943571126a44bb9e5aView in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 20V, Negativesplash10-004i-0900000000-bc12ce29acd02fa749b8View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 30V, Negativesplash10-03k9-0900000000-d63f60043f186fbb9bc0View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 40V, Negativesplash10-070l-4900000000-d293ab2fa6199dbaf97aView in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 50V, Negativesplash10-05ru-9400000000-dde4775588d52c83806fView in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 10V, Negativesplash10-004i-0900000000-556e382f583d610ef1f0View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 20V, Negativesplash10-004i-0900000000-89e34f5158856ba33469View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 30V, Negativesplash10-03k9-0900000000-65a6897d72954e875b00View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 40V, Negativesplash10-070l-4900000000-df16604bd6c40cee8f24View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 50V, Negativesplash10-05r3-9500000000-39a721dcecc86ed95507View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 10V, Positivesplash10-001i-1900000000-e67ff7ef9a955b90eb3fView in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 20V, Positivesplash10-001i-3900000000-1870952d98dbba22ace8View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 30V, Positivesplash10-00di-7900000000-dc0e9606776c43a7823fView in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 40V, Positivesplash10-014j-9300000000-2c4c6490dda3ed3b563fView in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 50V, Positivesplash10-014i-9000000000-26a6c0c23a465afdcde1View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 10V, Positivesplash10-01q9-1900000000-b11ca3441bb29fef1906View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 20V, Positivesplash10-0002-9400000000-63726fe0b49a9dc6ba7eView in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 30V, Positivesplash10-00di-9100000000-139f765bc9b5855960c6View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 40V, Positivesplash10-00di-9000000000-88b5cb393b960973ac64View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 50V, Positivesplash10-00yi-9000000000-1ebbddce3c7133972546View in MoNA
MSMass Spectrum (Electron Ionization)splash10-00lr-9500000000-2c8464c2fe84464c207fView in MoNA
1D NMR1H NMR SpectrumNot Available
1D NMR1H NMR SpectrumNot Available
1D NMR13C NMR SpectrumNot Available
2D NMR[1H,13C] 2D NMR SpectrumNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as alkaloids and derivatives. These are naturally occurring chemical compounds that contain mostly basic nitrogen atoms. This group also includes some related compounds with neutral and even weakly acidic properties. Also some synthetic compounds of similar structure are attributed to alkaloids. In addition to carbon, hydrogen and nitrogen, alkaloids may also contain oxygen, sulfur and more rarely other elements such as chlorine, bromine, and phosphorus.
KingdomOrganic compounds
Super ClassAlkaloids and derivatives
ClassNot Available
Sub ClassNot Available
Direct ParentAlkaloids and derivatives
Alternative Parents
Substituents
  • Alkaloid or derivatives
  • Xanthine
  • Purinone
  • 6-oxopurine
  • Purine
  • Imidazopyrimidine
  • Pyrimidone
  • Pyrimidine
  • Heteroaromatic compound
  • Vinylogous amide
  • Imidazole
  • Azole
  • Urea
  • Lactam
  • Azacycle
  • Organoheterocyclic compound
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Purine nucleoside binding
Specific Function:
Receptor for adenosine. The activity of this receptor is mediated by G proteins which inhibit adenylyl cyclase.
Gene Name:
ADORA1
Uniprot ID:
P30542
Molecular Weight:
36511.325 Da
References
  1. Nantwi KD, Basura GJ, Goshgarian HG: Adenosine A1 receptor mRNA expression and the effects of systemic theophylline administration on respiratory function 4 months after C2 hemisection. J Spinal Cord Med. 2003 Winter;26(4):364-71. [PubMed:14992338 ]
  2. Daly JW, Jacobson KA, Ukena D: Adenosine receptors: development of selective agonists and antagonists. Prog Clin Biol Res. 1987;230:41-63. [PubMed:3588607 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Identical protein binding
Specific Function:
Receptor for adenosine. The activity of this receptor is mediated by G proteins which activate adenylyl cyclase.
Gene Name:
ADORA2A
Uniprot ID:
P29274
Molecular Weight:
44706.925 Da
References
  1. Pechlivanova DM, Georgiev VP: Effects of single and long-term theophylline treatment on the threshold of mechanical nociception: contribution of adenosine A1 and alpha2-adrenoceptors. Methods Find Exp Clin Pharmacol. 2005 Nov;27(9):659-64. [PubMed:16357952 ]
  2. Daly JW, Jacobson KA, Ukena D: Adenosine receptors: development of selective agonists and antagonists. Prog Clin Biol Res. 1987;230:41-63. [PubMed:3588607 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
G-protein coupled adenosine receptor activity
Specific Function:
Receptor for adenosine. The activity of this receptor is mediated by G proteins which activate adenylyl cyclase.
Gene Name:
ADORA2B
Uniprot ID:
P29275
Molecular Weight:
36332.655 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Philipp S, Yang XM, Cui L, Davis AM, Downey JM, Cohen MV: Postconditioning protects rabbit hearts through a protein kinase C-adenosine A2b receptor cascade. Cardiovasc Res. 2006 May 1;70(2):308-14. Epub 2006 Feb 23. [PubMed:16545350 ]
  3. Phelps PT, Anthes JC, Correll CC: Characterization of adenosine receptors in the human bladder carcinoma T24 cell line. Eur J Pharmacol. 2006 Apr 24;536(1-2):28-37. Epub 2006 Mar 3. [PubMed:16581066 ]
  4. Fozard JR, Baur F, Wolber C: Antagonist pharmacology of adenosine A2B receptors from rat, guinea pig and dog. Eur J Pharmacol. 2003 Aug 15;475(1-3):79-84. [PubMed:12954362 ]
  5. Holgate ST: The Quintiles Prize Lecture 2004. The identification of the adenosine A2B receptor as a novel therapeutic target in asthma. Br J Pharmacol. 2005 Aug;145(8):1009-15. [PubMed:15980878 ]
  6. Daly JW, Jacobson KA, Ukena D: Adenosine receptors: development of selective agonists and antagonists. Prog Clin Biol Res. 1987;230:41-63. [PubMed:3588607 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Metal ion binding
Specific Function:
Hydrolyzes the second messenger cAMP, which is a key regulator of many important physiological processes. May be involved in mediating central nervous system effects of therapeutic agents ranging from antidepressants to antiasthmatic and anti-inflammatory agents.
Gene Name:
PDE4B
Uniprot ID:
Q07343
Molecular Weight:
83342.695 Da
References
  1. Lipworth BJ: Phosphodiesterase-4 inhibitors for asthma and chronic obstructive pulmonary disease. Lancet. 2005 Jan 8-14;365(9454):167-75. [PubMed:15639300 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Metal ion binding
Specific Function:
Plays a role in signal transduction by regulating the intracellular concentration of cyclic nucleotides. This phosphodiesterase catalyzes the specific hydrolysis of cGMP to 5'-GMP (PubMed:9714779, PubMed:15489334). Specifically regulates nitric-oxide-generated cGMP (PubMed:15489334).
Gene Name:
PDE5A
Uniprot ID:
O76074
Molecular Weight:
99984.14 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Metal ion binding
Specific Function:
Hydrolyzes the second messenger cAMP, which is a key regulator of many important physiological processes.
Gene Name:
PDE4A
Uniprot ID:
P27815
Molecular Weight:
98142.155 Da
References
  1. Wang K, Chen JQ, Chen Z, Chen JC: Inhibition of human phosphodiesterase 4A expressed in yeast cell GL62 by theophylline, rolipram, and acetamide-45. Acta Pharmacol Sin. 2002 Nov;23(11):1013-7. [PubMed:12421478 ]
  2. Haider S: Cyclic AMP level and phosphodiesterase activity during 17alpha,20beta-dihydroxy-4-pregnen-3-one induction and theophylline inhibition of oocyte maturation in the catfish, Clarias batrachus. Comp Biochem Physiol A Mol Integr Physiol. 2003 Feb;134(2):267-74. [PubMed:12547256 ]
  3. Rickards KJ, Andrews MJ, Waterworth TH, Alexander GB, Cunningham FM: Differential effects of phosphodiesterase inhibitors on platelet activating factor (PAF)- and adenosine diphosphate (ADP)-induced equine platelet aggregation. J Vet Pharmacol Ther. 2003 Aug;26(4):277-82. [PubMed:12887610 ]
  4. Usta C, Sadan G, Tuncel B: The effect of the indomethacin on phosphodiesterase inhibitors mediated responses in isolated trachea preparations. Prostaglandins Leukot Essent Fatty Acids. 2004 Sep;71(3):137-41. [PubMed:15253881 ]
  5. Lee JM, Zemans RL, Hejazi M, Chin BB, Ladenson PW, Caturegli P: Modulation of thyroidal radioiodine uptake by theophylline. Exp Mol Pathol. 2004 Oct;77(2):116-20. [PubMed:15351234 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Metal ion binding
Specific Function:
Cyclic nucleotide phosphodiesterase with a dual-specificity for the second messengers cAMP and cGMP, which are key regulators of many important physiological processes.
Gene Name:
PDE3A
Uniprot ID:
Q14432
Molecular Weight:
124978.06 Da
References
  1. Rickards KJ, Andrews MJ, Waterworth TH, Alexander GB, Cunningham FM: Differential effects of phosphodiesterase inhibitors on platelet activating factor (PAF)- and adenosine diphosphate (ADP)-induced equine platelet aggregation. J Vet Pharmacol Ther. 2003 Aug;26(4):277-82. [PubMed:12887610 ]
  2. Wu BN, Lin RJ, Lo YC, Shen KP, Wang CC, Lin YT, Chen IJ: KMUP-1, a xanthine derivative, induces relaxation of guinea-pig isolated trachea: the role of the epithelium, cyclic nucleotides and K+ channels. Br J Pharmacol. 2004 Aug;142(7):1105-14. Epub 2004 Jul 5. [PubMed:15237094 ]
  3. Kajikawa S, Kigami D, Nakayama H, Doi K: Changes in submaxillary gland gene expression in F344 rats by multiple dosing of theophylline. Exp Anim. 2006 Apr;55(2):143-6. [PubMed:16651698 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
activator
General Function:
Transcription factor binding
Specific Function:
Responsible for the deacetylation of lysine residues on the N-terminal part of the core histones (H2A, H2B, H3 and H4). Histone deacetylation gives a tag for epigenetic repression and plays an important role in transcriptional regulation, cell cycle progression and developmental events. Histone deacetylases act via the formation of large multiprotein complexes. Forms transcriptional repressor c...
Gene Name:
HDAC2
Uniprot ID:
Q92769
Molecular Weight:
55363.855 Da
References
  1. Ito K, Lim S, Caramori G, Cosio B, Chung KF, Adcock IM, Barnes PJ: A molecular mechanism of action of theophylline: Induction of histone deacetylase activity to decrease inflammatory gene expression. Proc Natl Acad Sci U S A. 2002 Jun 25;99(13):8921-6. Epub 2002 Jun 17. [PubMed:12070353 ]
  2. Cosio BG, Tsaprouni L, Ito K, Jazrawi E, Adcock IM, Barnes PJ: Theophylline restores histone deacetylase activity and steroid responses in COPD macrophages. J Exp Med. 2004 Sep 6;200(5):689-95. Epub 2004 Aug 30. [PubMed:15337792 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Brosen K: Drug interactions and the cytochrome P450 system. The role of cytochrome P450 1A2. Clin Pharmacokinet. 1995;29 Suppl 1:20-5. [PubMed:8846619 ]
  2. Wang B, Zhou SF: Synthetic and natural compounds that interact with human cytochrome P450 1A2 and implications in drug development. Curr Med Chem. 2009;16(31):4066-218. [PubMed:19754423 ]
  3. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  4. Sarkar MA, Hunt C, Guzelian PS, Karnes HT: Characterization of human liver cytochromes P-450 involved in theophylline metabolism. Drug Metab Dispos. 1992 Jan-Feb;20(1):31-7. [PubMed:1346993 ]
  5. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitorinducer
General Function:
Zinc ion binding
Specific Function:
Catalyzes the hydrolytic deamination of adenosine and 2-deoxyadenosine. Plays an important role in purine metabolism and in adenosine homeostasis. Modulates signaling by extracellular adenosine, and so contributes indirectly to cellular signaling events. Acts as a positive regulator of T-cell coactivation, by binding DPP4. Its interaction with DPP4 regulates lymphocyte-epithelial cell adhesion.
Gene Name:
ADA
Uniprot ID:
P00813
Molecular Weight:
40764.13 Da
References
  1. Saboury AA, Bagheri S, Ataie G, Amanlou M, Moosavi-Movahedi AA, Hakimelahi GH, Cristalli G, Namaki S: Binding properties of adenosine deaminase interacted with theophylline. Chem Pharm Bull (Tokyo). 2004 Oct;52(10):1179-82. [PubMed:15467230 ]
  2. Singh LS, Sharma R: Purification and characterization of intestinal adenosine deaminase from mice. Mol Cell Biochem. 2000 Jan;204(1-2):127-34. [PubMed:10718633 ]
  3. Bandyopadhyay BC, Poddar MK: Theophylline-induced changes in mammalian adenosine deaminase activity and corticosterone status: possible relation to immune response. Methods Find Exp Clin Pharmacol. 1997 Apr;19(3):181-4. [PubMed:9203166 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Metabolizes several precarcinogens, drugs, and solvents to reactive metabolites. Inactivates a number of drugs and xenobiotics and also bioactivates many xenobiotic substrates to their hepatotoxic or carcinogenic forms.
Gene Name:
CYP2E1
Uniprot ID:
P05181
Molecular Weight:
56848.42 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Sarkar MA, Hunt C, Guzelian PS, Karnes HT: Characterization of human liver cytochromes P-450 involved in theophylline metabolism. Drug Metab Dispos. 1992 Jan-Feb;20(1):31-7. [PubMed:1346993 ]
  3. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Vitamin d 24-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP1A1
Uniprot ID:
P04798
Molecular Weight:
58164.815 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, retinoid and xenobiotics. Preferentially oxidizes 17beta-estradiol to the carcinogenic 4-hydroxy derivative, and a variety of procarcinogenic compou...
Gene Name:
CYP1B1
Uniprot ID:
Q16678
Molecular Weight:
60845.33 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. In the epoxidation of arachidonic acid it generates only 14,15- and 11,12-cis-epoxyeicosatrienoic acids. It is the principal enzyme...
Gene Name:
CYP2C8
Uniprot ID:
P10632
Molecular Weight:
55824.275 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Mediates sodium-independent multispecific organic anion transport. Transport of prostaglandin E2, prostaglandin F2, tetracycline, bumetanide, estrone sulfate, glutarate, dehydroepiandrosterone sulfate, allopurinol, 5-fluorouracil, paclitaxel, L-ascorbic acid, salicylate, ethotrexate, and alpha-ketoglutarate.
Gene Name:
SLC22A7
Uniprot ID:
Q9Y694
Molecular Weight:
60025.025 Da
References
  1. Kobayashi Y, Sakai R, Ohshiro N, Ohbayashi M, Kohyama N, Yamamoto T: Possible involvement of organic anion transporter 2 on the interaction of theophylline with erythromycin in the human liver. Drug Metab Dispos. 2005 May;33(5):619-22. Epub 2005 Feb 11. [PubMed:15708966 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23